Study shows promise of precision medicine for most common type of lymphoma

A clinical trial has shown that patients with a specific molecular subtype of diffuse large B-cell lymphoma are more likely to respond to the drug ibrutinib than patients with another molecular subtype of the disease …read more

Source:: Cancer